Mutations in the PCNA-binding site of CDKN1C inhibit cell proliferation by impairing the entry into S phase

Abstract\ud \ud CDKN1C (also known as P57\ud \ud kip2\ud ) is a cyclin-dependent kinase inhibitor that functions as a negative regulator of cell proliferation through G1 phase cell cycle arrest. Recently, our group described gain-of-function mutations in the PCNA-binding site of CDKN1C that result in an undergrowth syndrome called IMAGe Syndrome (Intrauterine Growth Restriction, Metaphyseal dysplasia, Adrenal hypoplasia, and Genital anomalies), with life-threatening consequences. Loss-of-function mutations in CDKN1C have been identified in 5-10% of individuals with Beckwith-Wiedemann syndrome (BWS), an overgrowth disorder with features that are the opposite of IMAGe syndrome. Here, we investigate the effects of IMAGe-associated mutations on protein stability, cell cycle progression and cell proliferation. Mutations in the PCNA-binding site of CDKN1C significantly increase CDKN1C protein stability and prevent cell cycle progression into the S phase. Overexpression of either wild-type or BWS-mutant CDKN1C inhibited cell proliferation. However, the IMAGe-mutant CDKN1C protein decreased cell growth significantly more than both the wild-type or BWS protein. These findings bring new insights into the molecular events underlying IMAGe syndrome.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP process number 2012/09391-0

β-catenin-driven differentiation is a tissue-specific epigenetic vulnerability in adrenal cancer

http://deepblue.lib.umich.edu/bitstream/2027.42/176177/2/292502_2_merged_pdf_8667903_rt1d18.pdfAccepted versionDescription of 292502_2_merged_pdf_8667903_rt1d18.pdf : Submitted versio